Drug-Resistant Melanoma Acquires Exploitable Vulnerability

Cancer cells that develop resistance to one or more drugs will simultaneously develop a new weakness that could feasibly make them susceptible to other anticancer treatments. The trick is knowing what that new vulnerability is and how to exploit it. Scientists headed by a team at the Oncode Institute and Netherlands Cancer Institute have now identified a weakness that emerges in BRAF-mutant melanoma cells as they develop resistance to BRAF inhibitor therapy. The drug-resistant cells produce more